| Analysis | Metabolite Name | Measured Value | Units | CASE_CONTROL | Chemotherapy | Drug | Race | TIMEPOINT | Tamoxyfen | Taxane |
|---|---|---|---|---|---|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 1410 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 1711 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 1731 | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 1871 | Peak area | Case | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 2125 | Peak area | Case | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 2608 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 2765 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 3194 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 3616 | Peak area | Control | Y | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 4416 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 4919 | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 5524 | Peak area | Case | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 5632 | Peak area | Case | Y | Exemestane | Black | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6030 | Peak area | Control | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6062 | Peak area | Control | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6339 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6502 | Peak area | Case | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6673 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 6845 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 7065 | Peak area | Case | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 7151 | Peak area | Control | Y | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 7308 | Peak area | Case | Y | Exemestane | Black | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 7503 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 7562 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 8315 | Peak area | Case | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 8595 | Peak area | Case | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 8646 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 8707 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 8785 | Peak area | Case | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9009 | Peak area | Case | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9164 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9269 | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9347 | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9369 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9701 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9702 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9703 | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9736 | Peak area | Control | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 9769 | Peak area | Case | N | Letrozole | Black | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10116 | Peak area | Case | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10214 | Peak area | Control | Y | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10338 | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10479 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10497 | Peak area | Case | N | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10523 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10676 | Peak area | Control | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 10871 | Peak area | Control | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 11309 | Peak area | Case | Y | Exemestane | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 11576 | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12027 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12318 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12329 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12462 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12702 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12731 | Peak area | Control | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12872 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 12912 | Peak area | Control | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 13018 | Peak area | Control | Y | Exemestane | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 13149 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 13837 | Peak area | Control | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 14018 | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 14697 | Peak area | Control | Y | Exemestane | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 14713 | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 14734 | Peak area | Case | Y | Exemestane | White | Baseline | N | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 14826 | Peak area | Control | N | Letrozole | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 15147 | Peak area | Control | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 15565 | Peak area | Control | Y | Letrozole | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 16190 | Peak area | Case | N | Letrozole | Black | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 16306 | Peak area | Control | N | Exemestane | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 16369 | Peak area | Control | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 16909 | Peak area | Case | N | Exemestane | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 17756 | Peak area | Control | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 17862 | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 17995 | Peak area | Case | N | Exemestane | White | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 18505 | Peak area | Control | N | Exemestane | Black | 3 Month | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 20487 | Peak area | Control | Y | Letrozole | White | Baseline | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 21289 | Peak area | Case | N | Letrozole | White | Baseline | Y | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 22069 | Peak area | Case | N | Exemestane | Black | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 29222 | Peak area | Control | Y | Exemestane | White | 3 Month | Y | Y |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 33995 | Peak area | Case | N | Letrozole | White | Baseline | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | 38224 | Peak area | Case | N | Letrozole | White | 3 Month | N | N |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | N | Exemestane | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | N | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | N | Letrozole | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | N | Letrozole | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | Y | Exemestane | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | Y | Letrozole | White | 3 Month | Y | Y | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Case | Y | Letrozole | White | Baseline | Y | Y | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | N | Exemestane | Black | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | N | Exemestane | White | Baseline | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | N | Letrozole | Black | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | N | Letrozole | Black | Baseline | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | N | Y | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | Y | Exemestane | White | 3 Month | Y | N | |
| Reversed phase POSITIVE ION MODE | N-ALPHA-ACETYL-L-LYSINE (CAS# 1946-82-3); (M+H)+ | Peak area | Control | Y | Exemestane | White | Baseline | N | N |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|